DEFUSE 3研究中的血管内治疗
本研究分析DEFUSE 3研究中随机接受血管内治疗患者的血管造影结果与临床及影像结局的关系。92例患者中70例(76%)达到TICI 2B-3再灌注,TICI 2B-3组Rankin评分分布优于TICI 0-2A组(OR 2.77,95%CI 1.17-6.56,P=0.019),TICI 3患者较TICI 2B患者残疾更少(P=0.037)。成功再灌注与所用器械、闭塞部位或颈动脉血管成形及支架辅助使用无关。
要点
- 延长时间窗内取栓的TICI 2B-3再灌注率为76%(70/92),与早期时间窗研究相似。
- TICI 2B-3再灌注较TICI 0-2A有更有利的Rankin评分分布(OR 2.77,95%CI 1.17-6.56,P=0.019)。
- TICI 3患者24小时梗死增长显著少于TICI 0-2A(P=0.0015)和TICI 2B(P=0.0002)患者。
核心结论
- 延长时间窗内取栓的TICI 2B-3再灌注率与早期时间窗研究相似。
- 成功再灌注与所用器械、闭塞部位或颈动脉血管成形及支架辅助使用无关。
- TICI 3再灌注更可能带来24小时低梗死增长率和90天良好功能结局。
研究设计与样本
- DEFUSE 3研究(缺血性卒中影像评估后血管内治疗3)的血管造影分析,评估随机接受血管内治疗患者的基线及最终改良TICI评分。
- 共92例患者,评估主要动脉闭塞病变和改良TICI评分,临床结局采用90天改良Rankin量表序贯分析和功能独立(mRS 0-2)二分类分析。
主要发现
- TICI 2B-3再灌注 achieved 70/92例(76%)。
- TICI 2B-3再灌注较TICI 0-2A显示更有利的Rankin评分分布(OR 2.77,95%CI 1.17-6.56,P=0.019)。
- 良好功能结局(90天mRS 0-2)随TICI评分改善而增加(P=0.0028)。
- TICI 3患者较TICI 2B患者残疾更少(P=0.037)。
- TICI 3患者24小时梗死增长显著少于TICI 0-2A患者(P=0.0015)和TICI 2B患者(P=0.0002)。
关键数值与推荐
- TICI 2B-3再灌注率76%(70/92)。
- TICI 2B-3 vs TICI 0-2A的Rankin评分分布OR 2.77(95%CI 1.17-6.56,P=0.019)。
- 良好功能结局随TICI评分改善而增加(P=0.0028)。
- TICI 3 vs TICI 2B残疾更少(P=0.037)。
- 24小时梗死增长:TICI 3 vs TICI 0-2A P=0.0015;TICI 3 vs TICI 2B P=0.0002。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Endovascular therapy in an extended time window has been shown to be beneficial in selected patients. This study correlated angiographic outcomes of patients randomized to endovascular therapy with clinical and imaging outcomes in the DEFUSE 3 study (Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3). Methods- Angiograms were assessed for the primary arterial occlusive lesion and the modified Thrombolysis in Cerebral Infarction (TICI) score at baseline and the final modified TICI score. Clinical outcomes were assessed using an ordinal analysis of 90-day modified Rankin Scale and a dichotomous analysis for functional independence (modified Rankin Scale score of 0-2). TICI scores were correlated with outcome, types of device used for thrombectomy, and 24-hour follow-up imaging. Results- TICI 2B-3 reperfusion was achieved in 70 of 92 patients (76%). TICI 2B-3 reperfusion showed a more favorable distribution of Rankin scores compared with TICI 0-2A; odds ratio, 2.77; 95% confidence interval, 1.17-6.56; P=0.019. Good functional outcome (90-day modified Rankin Scale score of 0-2) increased with better TICI scores ( P=0.0028). There was less disability comparing TICI 3 patients to TICI 2B patients ( P=0.037). Successful reperfusion (TICI 2B-3) was independent of the device used, the site of occlusion (internal carotid artery or M1) or adjunctive use of carotid angioplasty and stenting. Significantly less infarct growth at 24 hours was seen in TICI 3 patients compared with TICI 0-2A ( P=0.0015) and TICI 2B ( P=0.0002) patients. Conclusions- Thrombectomy in an extended time window demonstrates similar rates of TICI 2B-3 reperfusion to earlier time window studies. Successful reperfusion was independent of the device used, the site of occlusion or adjunctive use of carotid angioplasty and stenting. TICI 3 reperfusion was more likely to result in low rates of infarct growth at 24 hours and good functional outcome at 90 days. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02586415.
引用
- Marks MP, Heit JJ, Lansberg MG, et al. Endovascular Treatment in the DEFUSE 3 Study. Stroke. 2018. PMID: 29986935. doi:10.1161/STROKEAHA.118.022147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。